Inserm is ranked 9th in the Reuters/Clarivate “Top 25 Global Innovators – Government,” which evaluates the innovative capacity of public bodies according to the impact of their scientific output and patents.
The Top 25 ranking just published on 1 March 2017 covers the 25 public institutions that contribute most to scientific and technological advancement worldwide. It is based on measurement of the volume and impact of the patents and scientific publications produced by 600 public bodies.
For France, the Alternative Energies and Atomic Energy Commission (CEA) was ranked 2nd, the National Centre for Scientific Research (CNRS) 8th and Inserm 9th. The US Department of Health and Human Services (HHS), which is responsible for intellectual property matters on behalf of NIH and CDC, has risen from 4th place (in 2016) to first place in 2017. Germany’s Fraunhofer Society, a multi-institute research organisation, is ranked third, ahead of the Japan Science and Technology Agency.
The United States and Germany each have five institutions ranked in the top 25, France and Japan each have four, and Australia, Canada, China, Singapore, South Korea, Spain and the United Kingdom each have just one. European institutions account for 11, compared with 8 in the Asia-Pacific region and 6 in North America.
About the ranking methodology
The Top 25 Global Innovators – Government ranking is published by Reuters, and performed in partnership with Clarivate Analytics (formerly the “Intellectual Property and Science” division of Thomson Reuters). It is based on exclusive data and analysis of indicators, including measurement of the number of patents filed, how often patents were granted, number of citations of patents and of academic articles in patents, and number of scientific articles. It is based on an analysis of data from 600 academic or government institutions
Explore the outer limits of the brain and matter, create unlimited energy, overcome pain, simulate the unattainable, etc. subjects dear to science fiction that are a now a reality for research laboratories! ...
Paris, March 21st, 2017 – Stimunity, Institut Curie and Inserm are pleased to announce that the company has signed an exclusive worldwide license agreement on two key patents that cover Stimunity’s core technology VLP-cGAMP to develop new drugs in immuno-oncology. ...